Sou Moua v. HHS - Influenza, atypical Guillain-Barre Syndrome (“GBS”) and/or Acute and/or Chronic Inflammatory Demyelinating Polyneuropathy (“AIDP” and “CIDP”) (2024)

Sou Moua filed a petition on March 3, 2021, alleging that an influenza vaccine administered on October 3, 2018, caused him to develop atypical Guillain-Barre Syndrome (GBS) and/or Acute and/or Chronic Inflammatory Demyelinating Polyneuropathy (AIDP and CIDP). The respondent, the Secretary of Health and Human Services, denied that the vaccine caused the alleged injuries.

Despite this denial, the parties reached a stipulation for compensation, which was filed on February 1, 2024. Special Master Herbrina Sanders reviewed the stipulation and found it reasonable, adopting it as the decision of the Court.

The award consists of a lump sum payment of $175,000.00 payable to Sou Moua and an additional $175,000.00 to purchase an annuity contract. This total compensation of $350,000.00 covers all damages available under the National Vaccine Injury Compensation Program.

The decision was issued on February 6, 2024. The public decision does not describe the petitioner's counsel, respondent's counsel, the specific onset of symptoms, clinical details, medical tests, treatments, or expert testimony.

The theory of causation is not detailed in the public decision.